AMPE (Ampio Pharmaceuticals) Short-Term Debt: $0.00 Mil (As of Dec. 2023)


What is Ampio Pharmaceuticals Short-Term Debt?

Ampio Pharmaceuticals AMPE -71.39% Short-Term Debt is $0.00 Mil as of Dec. 2023.

Ampio Pharmaceuticals's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Ampio Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Ampio Pharmaceuticals Short-Term Debt Related Terms

Ampio Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Ampio Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ampio Pharmaceuticals Short-Term Debt Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Ampio Pharmaceuticals (AMPE) has a Short-Term Debt of $0.00 Mil as of Dec. 2023.
Is Ampio Pharmaceuticals' Short-Term Debt too high?
Ampio Pharmaceuticals' current Short-Term Debt is $0.00 Mil.
How does Ampio Pharmaceuticals' Short-Term Debt compare to EFTR and VBIVQ?
Ampio Pharmaceuticals' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Ampio Pharmaceuticals's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ampio Pharmaceuticals stock overvalued right now?
Ampio Pharmaceuticals (AMPE) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Ampio Pharmaceuticals (AMPE), the current Short-Term Debt is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ampio Pharmaceuticals Business Description

Address 9800 Mount Pyramid Court, Suite 400, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee (OAK) as part of its OA-201 development program (OA-201 program or OA-201).